Table 5.
All-causality adverse events including all grades (n, %) in all cycles and occurring in ≥2 patients (grade 3/4) for Schedule 2/1 at the MTD (sunitinib 37.5 mg + docetaxel 75 mg/m2 q21d)
| Adverse event | Schedule 2/1 MTD (N = 23) | |||
|---|---|---|---|---|
| Grade 1 n (%) | Grade 2 n (%) | Grade 3 n (%) | Grade 4 n (%) | |
| Neutropenia | 0 | 2 (8.7) | 0 | 15 (65.2) |
| Fatigue | 4 (17.4) | 7 (30.4) | 5 (21.7) | 0 |
| Febrile neutropenia | 0 | 0 | 1 (4.3) | 2 (8.7) |
| Hyperglycemia | 1 (4.3) | 4 (17.4) | 3 (13.0) | 0 |
| Leukopenia | 0 | 1 (4.3) | 1 (4.3) | 1 (4.3) |
| Hypokalaemia | 0 | 0 | 3 (13.0) | 0 |
| Diarrhea | 5 (21.7) | 6 (26.1) | 2 (8.7) | 0 |
| Pyrexia | 7 (30.4) | 4 (17.4) | 2 (8.7) | 0 |